Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide is an injectable medication available as Ozempic and Rybelsus to treat type 2 diabetes and Wegovy for managing overweight or obesity. GLP-1 is a hormone produced by the intestines ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

The FDA and drugmaker Novo Nordisk on Monday warned that counterfeit vials of Ozempic® (semaglutide) are being sold to consumers and may cause a safety risk. Novo Nordisk cautions pharmacies and ...

Currently, only 1 in 4 employers offer insurance coverage for GLP-1 drugs for weight management—with variability in ease of access, due to step therapy and prior authorization requirements ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

The frequency of blurred vision and visual impairment was relatively high with both formulations of semaglutide; adverse drug events related to the retina were more common with subcutaneous ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT ...